Tom NatoliSenior Director of Genetic Medicines at Dyne TherapeuticsSpeaker
Agenda Sessions
Advancing RNA Therapeutics for FSHD: DUX4 Targeting, Biomarker Innovation, and Translation to the Clinic
, 11:50amView Session
